

CONTRIBUTORS

ASHORN, PER
Laboratory of Viral Diseases
National Institute of Allergy
and Infectious Diseases
National Institute of Health
Bethesda, Maryland

BARIGHT, DONALD E.
Department of Virology
Sterling Research Group
Rensselaer, New York

BERGER, EDWARD A.
Laboratory of Viral Diseases
National Institute of Allergy
and Infectious Diseases
National Institute of Health
Bethesda, Maryland

BLOCK, TIMOTHY M.
Department of Microbiology
and Immunology
Jefferson Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania

BRIGANDI, RICHARD A.
Department of Microbiology
and Immunology
Jefferson Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania

CANTIN, EDOUARD M.
City of Hope National Medical Center
Department of Neurology
Duarte, California

CHAMBERS, LORENA
Department of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

CHENG, Y.S. EDMOND
DuPont Merck Pharmaceutical Company
Wilmington, Delaware

COEN, DONALD M.
Department of Biological Chemistry
and Molecular Pharmacology
Harvard Medical School
Boston, Massachusetts

COLONNO, RICHARD J.
Department of Virus
and Cell Biology
Merck Sharp & Dohme
Research Laboratories
West Point, Pennsylvania

COTE, PAUL J.
Division of Molecular Virology
and Immunology
Department of Microbiology
Georgetown University
Rockville, Maryland

DE BOECK, HILDE
Bristol Myers-Squibb
Pharmaceutical Research Institute
Wallingford, Connecticut

DIANA, GUY D.
Department of Medicinal Chemistry
Sterling Research Group
Rensselaer, New York

DI NELLO, ROBERT
Chiron Corporation
Emeryville, California

DIRENZO, SUE
Department of Pathology
Thomas Jefferson University
Philadelphia, Pennsylvania

DURANTE, MARYANN
Department of Pathology
Thomas Jefferson University
Philadelphia, Pennsylvania

DUTKO, FRANK J.
Department of Virology
Sterling Research Group
Rensselaer, New York

EISENSTEIN, TOBY K.
Department of Microbiology
and Immunology
Temple University School of Medicine
Philadelphia, Pennsylvania

EPSY, MARK J.
Section of Clinical Microbiology
Mayo Clinic
Rochester, Minnesota

FIELDS, BERNARD N.
Harvard Medical School
Boston, Massachusetts

FOX, M. PAT
Department of Virology
Sterling Research Group
Rensselaer, New York

FRANCIS, BRIAN
Ortho Diagnostic Systems, Inc.
Raritan, New Jersey

FRIEDMAN, LAWRENCE S.
Division of Gastroenterology
and Hepatology
Jefferson Medical College
Philadelphia, Pennsylvania

GERIN, JOHN L.
Division of Molecular Virology
and Immunology
Department of Microbiology
Georgetown University
Rockville, Maryland

GRAFSTROM, ROBERT H.
Department of Microbiology
and Immunology
Jefferson Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania

HICKS, KAREN A.
Department of Biological Chemistry
and Molecular Pharmacology
Harvard Medical School
Boston, Massachusetts

HITCHCOCK, MICHAEL J.M.
Bristol Myers-Squibb
Pharmaceutical Research Institute
Wallingford, Connecticut

HO, HSU-TSO
Bristol Myers-Squibb
Pharmaceutical Research Institute
Wallingford, Connecticut

HOPKINS, LEIGH
Department of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

HSIEH, SEN-YUNG
Fox Chase Cancer Center
Philadelphia, Pennsylvania

INGEMARSON, ROLF
Department of Biochemistry
Bio-Mega Inc.
2100 rue Cunrad
Laval, Quebec, Canada

JUNGKIND, DONALD
Department of Pathology
Thomas Jefferson University
Philadelphia, Pennsylvania

KONRAD, SHERRY A.
Bristol Myers-Squibb
Pharmaceutical Research Institute
Wallingford, Connecticut

KORANT, BRUCE D.
DuPont Merck Pharmaceutical Company
Wilmington, Delaware

KORBA, BRENT E.
Division of Molecular Virology
and Immunology
Department of Microbiology
Georgetown University
Rockville, Maryland

LEE, STEPHEN
Ortho Diagnostic Systems, Inc.
Raritan, New Jersey

LIUZZI, MICHEL
Department of Biochemistry
Bio-Mega, Inc.
2100 rue Cunrad
Laval, Quebec, Canada

MARTIN, PAUL
Division of Gastroenterology
and Hepatology
Jefferson Medical College
Philadelphia, Pennsylvania

MC HUTCHINSON, JOHN
Division of GI and Liver Disease
University of Southern California
Los Angeles, California

MC KINLAY, MARK A.
Department of Virology
Sterling Research Group
Rensselaer, New York

MERLUZZI, VINCENT J.
Boehringer Ingelheim
Pharmaceuticals, Inc.
Ridgefield, Connecticut

MORAHAN, PAGE S.
Department of Microbiology
and Immunology
The Medical College of Pennsylvania
Philadelphia, Pennsylvania

MOSS, BERNARD
Laboratory of Viral Diseases
National Institute of Allergy
and Infectious Diseases
National Institute of Health
Bethesda, Maryland

NELLES, Mitchell
Ortho Diagnostic Systems, Inc.
Raritan, New Jersey

OPENSHAW HARRY
City of Hope National Medical Center
Department of Neurology
Duarte, California

OTTO, MICHAEL J.
DuPont Merck Pharmaceutical Co.
Wilmington, Delaware

PATTERSON, CATHERINE E.
DuPont Merck Pharmaceutical Co.
Wilmington, Delaware

PELOSI, EMANUELA
Department of Biological Chemistry
and Molecular Pharmacology
Harvard Medical School
Boston, Massachusetts

PERVEAR, DANIEL C.
Department of Virology
Sterling Research Group
Rensselaer, New York

PODSAKOFF, GREGORY
City of Hope Medical Center
Department of Neurology
Duarte, California

POLITO, ALAN
Chiron Corporation
Emeryville, California

QUAN, STELLA
Chiron Corporation
Emeryville, California

RINEHART, KENNETH L.
Department of chemistry
University of Illinois
Urbana, Illinois

RIZZO, CHRISTOPHER J.
DuPont Merck Pharmaceutical Co.
Wilmington, Delaware

ROSENTHAL, ALAN S.
Boehringer Ingelheim
Pharmaceuticals, Inc.
Ridgefield, Connecticut

ROSSI, JOHN J.
Department of Molecular Genetics
Beckman Research Institute
of the City of Hope
Duarte, California

ROTBART, HARLEY A.
University of Colorado
School of Medicine
Denver, Colorado

RUCKER, RONALD G.
DuPont Merck Pharmaceutical Co.
Wilmington, Delaware

SACKS, STEPHEN L.
Division of Infectious Diseases
University of British Columbia
Vancouver, British Columbia, Canada

SARVER, NAVA
Developmental Therapeutics Branch
Division of AIDS, NIAID
Bethesda, Maryland

SCOUTEN, ERIKA
Department of Biochemistry
Bio-Mega Inc.
2100 rue Cunrad
Laval, Quebec, Canada

SMITH, THOMAS F.
Section of Clinical Microbiology
Mayo Clinic
Rochester, Minnesota

TAYLOR, JOHN
Fox chase Cancer Center
Philadelphia, Pennsylvania

TENNANT, BUD C.
Department of Clinical Sciences
College of Veterinary Medicine
Cornell University
Ithaca, New York

WILLEY, DRU E.
City of Hope National Medical Center
Department of Neurology
Duarte, California

WOLD, ARLO D.
Section of Clinical Microbiology
Mayo Clinic
Rochester, Minnesota

WOODS, KATHLEEN L.
Bristol Myers-Squibb
Pharmaceutical Research Institute
Wallingford, Connecticut

WORDELL, CINDY
Department of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

WU, LINXIAN
Department of Microbiology
and Immunology
The Medical College of Pennsylvania
Philadelphia, Pennsylvania

ZACHARIASEWYCZ, KATHERINE
Department of Microbiology
and Immunology
The Medical College of Pennsylvania
Philadelphia, Pennsylvania

INDEX

- Acridine orange, 141
Acyclovir, 15, 56, 113, 115, 140, 151–158
Adenine arabinoside (Ara-A), 56, 57, 113
 monophosphate, 113, 115
Adeno-associated virus as vector, 108
 and gene therapy, 108
Adenosine arabinoside, 25
Adenosine-5'-diphosphate (ADP), 133
Adenosine triphosphate (ATP), 163
Adhesion molecule, intercellular (ICAM), 62–64
Adriamycin, 25
African green monkey kidney cells, *see* Cell line Vero
Ageliferins, 41–43
 structure, chemical, 42
Agent, antiviral, sources of, 41–60; *see also* specific compounds
AHCE, *see* Alpha Helix Caribbean Expedition
AIDS (acquired immunodeficiency syndrome), and drugs, 15; *see also* AZT
Alpha Helix Caribbean Expedition (Natl. Science Foundation, 1978), 41
 and agents, antiviral, 41–60
 phyla, thirteen, with activity listed, 42–43
Amanitin, alpha, 15
Ames assay for mutagenesis, 25, 29
Antibody
 detection by ELISA, 173–189
 IgG, 191–192
 IgM, 192
 monoclonal, 10–14, 134
Antisense, 139–149
 animal studies, 145–146
 gene, 141
 inhibition of virus replication, 141–146
 nucleic acid, 139–149
 phenotype, 141
Antiviral intervention, *see* Intervention
Aphidicolin, 152, 153
Aprotinin, 5–7
Ara-A, *see* Adenine arabinoside
Arabinosyl cytosine (Ara-C), 15
Ara-C, *see* Arabinosyl cytosine
Autocleavage domain of hammerhead, 96, 97
Autoproteolysis, 86
3'-Azido-2',3'-dideoxythymidine, *see* AZT
AZT (zidovudine), 15, 26, 77, 78, 89, 92, 117

Bacteria; *see also* *Escherichia coli*
 designer bacteria, 26
 engineered, genetically, 25–40
 as antiviral agents, 25–40
BI-RG-587, *see* Nevirapine
Blood
 cell, mononuclear, peripheral (PBMC), 93
 donor and hepatitis virus, 186, 188
Bone marrow transplant
 course, clinical, 153
 and infection, 151–158
Bryostatin-1, 56
 from Bryozoon, 56
 from *Bugula neritina*, 56, 57
Bryozoon *Bugula neritina*, 56
Camptothecin, 29
Canonic Rift Valley fever study, 49
Canyon
 hypothesis of virus attachment, 16, 64–65
 and mutagenesis, 65
Carcinoma, hepatocellular, 112, 117, 121
CD4 receptor, 71–79, 93
Cell line
 BHK-21, 132
 CEM, 159
 H-9, 83–88
 HeLa, 50
 JM-105, 84
 L-1210, 47
 Vero, 48, 142, 144, 152, 159–166, 168
Chloramphenicol acetyl transferase, 127
 mRNA, 127
Chymostatin, 4–7
Colchicine, 8, 10, 12
 antiviral, 10
Corticosteroid, 113
Corynebacterium parvum, 167
 killed vaccine, 168
Coxsackie virus strains, 22–23, 93, 47, 49, 50
 prototype Nancy and clinical isolates differ, 22–23
CPE, *see* Effect, cytopathic
Cycloheximide, 15
Cyclosporin A, 25, 45
Cytokine, 63, 171
Cytomegalovirus (CMV), 47, 129, 173–182, 193, 195
Cytosine arabinoside (Ara-C), 57

- Dearing strain of reovirus
 neurotropic, 8–10
 spread of, 8–10
- Debromooxysceptin, 43
- Decompensation, hepatic, 115
- Dehydrodidemnin, 45
- Delta virus, *see* Hepatitis virus, delta
- Dengue virus, 49
- Deoxyribonucleic acid, *see* DNA
- Designer bacteria, 26
- Diazepinone, tricyclic, 89
- Didemnins, 45–53, 57
 antiviral, 47
- Dideoxycytidine, 117
- Dipyridodiazepinone, 89
- Disoxaril (*WIN-51711*), 18, 19, 21
 structure, chemical, 18
- DNA, 84, 130, 161, 168, 170
 probe for viral diagnosis, 201–209
- DNA polymerase, 130, 161
- Doxorubicin, 146
- Drug as molecular tool, 15–24
see separate compounds
- Effect, cytopathogenic (CPE), 192
- EIA, *see* Enzyme immunoassay
- ELISA, 188
- Enterovirus, 192
- Enzyme immunoassay (EIA), 192–193
 kits, 192
- Epstein-Barr virus, 129, 192
 and liver graft infection, a case history, 195
- Equine rhinovirus, 47, 49, 50
- Escherichia coli*, 25–40, 83
 engineered, genetically, 25–40
- Esophagitis, 151–158
- Eudistomins, 43–45, 57
 antiviral, 44
 structure, chemical, 44
- Feline leukemia virus, 91
- Firefly (*Photinus* sp.), 56
- Fluorography, 5, 7
- Footpad of mouse
 inoculation, viral, 6, 9–13
- Foscarnet, 140, 151–158
 antiviral, 140
- Globulin, gamma, preparation, commercial,
 intravenous, 173–182
 and cytomegalovirus antibody, 173–182
 ELISA, 174, 177–180
- GMP, *see* Guanine monophosphate
- Gorgon *Pseudoplexaura homomalla*, 56
- Guanine monophosphate (GMP), 161, 163
- Guanylate kinase, 163–165
- Halichondrin B, 57
- Hammerhead concept, 95–97, 141
 and ribozyme, *trans*-acting, 98–100; *see also*
 Ribozyme
- HeLa cells and rhinovirus, 17, 19
- Hepadnavirus, 117, 118, 121–123
 reverse transcriptase, 117
 and thymosin, *alpha-1*, 121–123
 woodchuck model, 121–123
- Hepatitis, chronic, 112, 116–117, 125–128
 therapy, 112, 116, 117
- Hepatitis virus
 B, 111–120
 therapy, 111–120
 C, 183–189, 191
 in blood donors, 186, 188
 D, (delta), 125–128
 non-A, non1-B (NANB), *see* C
- Herpes, genital, 129
- Herpes virus, 42, 44, 192, 193
 agents, antiviral, 95–109, 129–149, 151–158
 and cytokine gene expression, 167–172
 ribonucleotide reductase inhibitor, 129–139
type-1, 47, 48, 53, 58, 129–139, 159, 167–172
type-2, 47, 48, 49, 52, 159
type-6, 129
type-7, 129
- Herpes simplex virus, 129–149
 antisense nucleic acids, 139–149
 disease spectrum, 139
 gene *IE3*, 139–149
 inhibition by synthetic nonapeptide, 129–139
 latency, 129, 139
 and ribonucleotide reductase, 129–139
 strain 615, clinical isolate, 151–158
 case history, 151–158
 therapy, 151–158
- HIV (human immunodeficiency virus), 63, 71–81,
 191
 and protease of *E. coli*, 25–28
 inhibitor, 29–35
- HIV-1*, 89–109
 agent, antiviral, 95–109
 and nevirapine, 89–94
 reverse transcriptase, 89–94
 and ribozyme, 95–109
- HIV-2*, 83–88, 92
 clones, 83–88
 protease, polymerase chain reaction, 83–88
- HRV, *see* Rhinovirus, human
- Hybrid arrest translation technique of, 141
- Hybridization by blotting, 167–171
- Hydroxyisovalerylpropionic acid, gamma (Hip),
 45
- IC-50*, 131–133
 calculation, 133
- Immunodeficiency virus human, *see* HIV
 simian, 91
- Immunofluorescence, 193–195
 assay, 168
 shell vial assay, 193–195
- Influenza virus, 47, 93, 192, 193
- Interferon, 63, 112–116
- Interleukin-2*, 63, 113
- Intervention, antiviral
 against reovirus, 1–14

- Isostatin, 45
 ISVP, *see* Reovirus particle
- Kinin, 63
- Latency, viral, 139, 140
 Leukemia virus, feline, 91
 Ligase, 95
 Liposome, 106, 107
 as viral vector, 125
 Liver graft recipient, 117
 dysfunction, case history, 195–196
 Lucibufagins, 55–56
 antiviral, 56
 structure, chemical, 55
 Lymphocyte *H-9*, 107
- Macrophage, murine, 167–172
 and herpes simplex virus, 167–172
Marmota monax, *see* Woodchuck
 MDBK cell line, 93
 Measles virus, 191, 192
 Microtubule and reovirus, 8
 Misakinolide, 54
 structure, chemical, 55
 Moloney murine leukemia virus, 169
 Monoalide, 56, 57
 from *Luffariella variabilis*, 57
 Monocyte, human, 93
 macrophage and antiviral resistance, 167–172
 Mucositis, 151–158
 MX protein, 113
 Mycalamide A, 57
 structure, chemical, 54
- NDP kinase, *see* Nucleoside
 Nevirapine (*BI-RG-587*), 89–94
 binding to reverse transcriptase, 90–91
 characteristics, 89–90
 Nonapeptide, synthetic, 129–139
 structure, chemical, 131
 Northern blot hybridization, 167–171
 Northern gel analysis, 107
 Nucleic acid; *see also* DNA, RNA
 antisense of herpes simplex virus, 139–149
 detection methods, 195–196
 hybridization, 202–207
 decision tree, 204–207
 principles, eight, 202–204
 Nucleoside diphosphate kinase (NDP), 164, 165
 Nucleoside phosphonate, 163
- Onnamide A, 54
 structure, chemical, 54
 2',5'-Oligoadenylate synthetase, 113
 Oligodeoxyribonucleoside methylphosphonate (OMP)
 antiviral, 139–149
 synthetic, 139–149
 Oxathiazepine, 44
 Oxysceptrins, 41–43
 structure, chemical, 42
- Palytoxin, 57
 Papillomavirus, 159
Parainfluenza-3 virus, 47–50
 PBMC, *see* Blood
 PCR, *see* Polymerase chain reaction
 Pederin, 54
 Pepstatin A, 29, 32, 45
 agarose affinity chromatography, 85–86
 PFA, 152–156
 Phosphodiesterase, alkaline, 168
 9-(2-Phosphonylmethoxyethyl)guanine, 159–166
 antiviral, 159–166
 metabolism, cellular, 159–166
 phosphorylation, 160, 162–165
 Pichinde virus, 49, 51
 Picornavirus, 16
 Plasmids, 84
 PMEG, *see* 9-(2-Phosphonylmethoxyethyl)guanine
 Poliovirus, human, 16, 93
 uncoating, 19–20
 Polymerase chain reaction, 195
 assay, 102, 103, 169
 and DNA amplification, 84
 Prednisone, 115
 and alpha-interferon, 115
 Probe for nucleic acid, 195
 Prostaglandin, 59
 Protease inhibitor, 4–7
 Proteolysis, 5
Pseudomonas aeruginosa, 40, 73, 74
 exotoxin, 40, 71, 73, 74
 Pseudopterosin B, 57
 Psoralen, 141
 Ptilocaulin, 57
 Pyruvate kinase, 161, 164, 165
- Rauscher murine leukemia virus, 159
 Reovirus, 1–14
 intervention, antiviral, 1–14
 pathogenesis, murine, 1–14
 spread within host, 6–8
 Retrovirus, 125
 reverse transcriptase, 117
 Reverse transcriptase, 89–94, 117, 169
 inhibitors, 75–79, 89–94
 Rhinovirus
 equine, 47, 49, 50
 human, 15–24, 61–70
 RIBA analysis, 188
 for hepatitis C virus, 184, 187
 Ribavirin, 49, 56
 Ribonucleic acid, *see* RNA
 Ribonucleotide reductase of herpes simplex virus,
 129–139
 Ribozyme (RNA, catalytic, antisense), 95–109, 125–
 128, 141, 144
 versus antisense, conventional, 103–108
 Ricin, 71, 73, 146
 Rift Valley fever virus, 49, 51, 53
 Canonico study, 49
 RNA, 95, 98–106, 125–128
 catalytic, 95, 141

- RNA (*cont'd*)
 as endoribonuclease, 125
- Rotavirus, 6
- Rous sarcoma virus, 141
- Rubella virus, 191, 192
- Salmonella typhimurium*, 167, 168
- Sandfly fever virus, 49
- Sceptrins, 41–43
 structure, chemical, 42
- Shell vial assay, 193–194
 variables, six, 194
- Sindbis virus, 125
- Site for antiviral intervention, 1–14
- Southern blot hybridization, 169
- Sponge as source of antivirals, 41–43, 54, 57
- Spongiadiol structure, 55
- Spongothymidine, 57
- Spongouridine, 57
- Statin, 45
- Suicide transport, 146
- T-cell, 93, 76, 77
- Tetracycline, 25, 27–30, 33–37
- Thymosin, 63
alpha-1, 121–123
- Thyrsiferol, 53–55
 structure, chemical, 55
- Thyrsiferol acetate, 53
- Topisomerase, 29
- Transplant recipient patient, 173
see Bone marrow
- Tunicates as source of antivirals, 43–45
- Vaccinia virus, 47, 125, 143–145
- Varicella zoster virus, 47, 129, 159, 191
- Venezuelan equine encephalomyelitis virus, 49, 51
- Venustatriol, 53
- Vero cell line, 48, 142, 144, 152, 159–166, 168
- Vesicular stomatitis virus, 53, 56
- Viroid, 95, 141
 hammerhead, 95–100
- Virology, diagnostic
 then and now, 191–199
- Virus, *see* separate viruses
- Virusoid, 95, 141
 hammerhead, 95–97
 replication, 96
- WIN compounds, 17–22
 structure, chemical, 18
- Woodchuck as model, 121–123, 128
- Yellow fever virus, 49, 51
- Zidovudine, *see* AZT